These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 16019547

  • 1. Bone lesions and macrophage inflammatory protein-1 alpha (MIP-1a) in human multiple myeloma.
    Hata H.
    Leuk Lymphoma; 2005 Jul; 46(7):967-72. PubMed ID: 16019547
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM.
    Uneda S, Hata H, Matsuno F, Harada N, Mitsuya Y, Kawano F, Mitsuya H.
    Br J Haematol; 2003 Jan; 120(1):53-5. PubMed ID: 12492576
    [Abstract] [Full Text] [Related]

  • 4. Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
    Terpos E, Politou M, Viniou N, Rahemtulla A.
    Leuk Lymphoma; 2005 Dec; 46(12):1699-707. PubMed ID: 16263571
    [Abstract] [Full Text] [Related]

  • 5. MIP-1 alpha and myeloma bone disease.
    Roodman GD, Choi SJ.
    Cancer Treat Res; 2004 Dec; 118():83-100. PubMed ID: 15043189
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.
    Giuliani N, Lisignoli G, Colla S, Lazzaretti M, Storti P, Mancini C, Bonomini S, Manferdini C, Codeluppi K, Facchini A, Rizzoli V.
    Cancer Res; 2008 Aug 15; 68(16):6840-50. PubMed ID: 18703490
    [Abstract] [Full Text] [Related]

  • 9. New insights in myeloma-induced osteolysis.
    Barillé-Nion S, Bataille R.
    Leuk Lymphoma; 2003 Sep 15; 44(9):1463-7. PubMed ID: 14565645
    [Abstract] [Full Text] [Related]

  • 10. [Bone disease in multiple myeloma and its mechanism].
    Abe M.
    Clin Calcium; 2006 Apr 15; 16(4):565- 71. PubMed ID: 16582506
    [Abstract] [Full Text] [Related]

  • 11. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N, Colla S, Rizzoli V.
    Exp Hematol; 2004 Aug 15; 32(8):685-91. PubMed ID: 15308315
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bone markers in multiple myeloma.
    Heider U, Fleissner C, Zavrski I, Kaiser M, Hecht M, Jakob C, Sezer O.
    Eur J Cancer; 2006 Jul 15; 42(11):1544-53. PubMed ID: 16765040
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
    Oyajobi BO, Mundy GR.
    Cancer; 2003 Feb 01; 97(3 Suppl):813-7. PubMed ID: 12548580
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.